Home > Microtubule/Tubulin & Microtubule/Tubulin & > ABT-751

ABT-751

E-7010,E7010,E 7010,ABT 751,ABT751,

ABT-751(E 7010)是新型的生物相容性的微管蛋白结合剂和抗有丝分裂磺胺类化合物，对神经母细胞瘤细胞株和非神经母细胞瘤细胞株的IC50分别为1.5 和 3.4 μM。

目录号
EY1829
EY1829
EY1829
EY1829
EY1829
纯度
99.74%
99.74%
99.74%
99.74%
99.74%
规格
5 mg
10 mg
25 mg
50 mg
100 mg
原价
490
720
1450
2100
3400
售价
490
720
1450
2100
3400
库存
现货
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    ABT-751 (E7010) binds to the colchicine site on β-tubulin and inhibits polymerization of microtubules, not a substrate for the MDR transporter and is active against cell lines resistant to vincristine, doxorubicin, and cisplatin. Phase 1/2.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0 -100 μM

  • 动物实验

    75 或100 mg/kg/day口服处理

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Meany HJ, et al. Pediatr Blood Cancer. 2010, 54(1), 47-54.
    [2] Holly J. Meany,et al. Clinical Outcome in Children with Recurrent Neuroblastoma Treated with ABT-751 and Effect of ABT-751 on Proliferation of Neuroblastoma Cell Lines and on Tubulin Polymerization In Vitro. Pediatr Blood Cancer. Author manuscript; available in PMC 2011 Jan 1. Published in final edited form as: Pediatr Blood Cancer. 2010 Jan; 54(1): 47–54. doi: 10.1002/pbc.22267.
    [3] Charles M. Rudin,et al. Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. J Clin Oncol. 2011 Mar 10; 29(8): 1075–1082. Published online 2011 Feb 7. doi: 10.1200/JCO.2010.32.5944.

    分子式
    C18H17N3O4S    		 分子量
    371.41    		 CAS号
    141430-65-1    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    ≥70 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    ≥10 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00471718 Prostate Cancer Drug: ABT-751 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Phase 1|Phase 2 2004-01-01 2012-06-27
    NCT00735878 Non Small Cell Lung Cancer|Advanced Lung Cancer Drug: ABT-751 and Carboplatin Dartmouth-Hitchcock Medical Center|Abbott Phase 1|Phase 2 2004-09-01 2009-04-29
    NCT00436852 Disseminated Neuroblastoma|Recurrent Neuroblastoma Drug: ABT-751|Procedure: quality-of-life assessment Children's Oncology Group|National Cancer Institute (NCI) Phase 2 2007-01-01 2017-01-30
    NCT00047489 Hematological Malignancies Drug: ABT-751 M.D. Anderson Cancer Center Phase 1 2002-12-01 2012-02-20
    NCT00073138 Colorectal Cancer Drug: ABT-751 Abbott Phase 2 2003-08-01 2007-11-28
    NCT00073112 Renal Cell Cancer Drug: ABT-751 Abbott Phase 2 2003-08-01 2007-11-28
    NCT00073151 Non-Small Cell Lung Cancer Drug: ABT-751 Abbott Phase 2 2003-09-01 2007-11-28
    NCT00036959 Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific Drug: ABT-751 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Phase 1 2002-03-01 2012-03-14
    NCT00063102 Breast Cancer Drug: ABT-751 Abbott Phase 2 2002-11-01 2007-11-28
    NCT00354562 Lung Cancer|Non-Small Cell Lung Cancer Drug: ABT-751|Drug: Placebo|Drug: Docetaxel Abbott Phase 1|Phase 2 2007-02-01 2011-01-05
    NCT00297089 Lung Cancer|NSCLC|Non-Small-Cell Lung Cancer Drug: ABT-751|Drug: pemetrexed|Drug: placebo AbbVie (prior sponsor, Abbott)|AbbVie Phase 1|Phase 2 2006-11-01 2013-01-29
    NCT00439296 Recurrent Pediatric ALL|Relapsed Pediatric ALL|Acute Lymphoblastic Leukemia|Refractory Pediatric ALL Drug: ABT-751|Drug: dexamethasone|Drug: PEG-asparaginase|Drug: doxorubicin|Drug: cytarabine|Drug: methotrexate|Drug: cyclophosphamide|Drug: 6-thioguanine Therapeutic Advances in Childhood Leukemia Consortium Phase 1 2006-05-01 2012-11-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：